Psychiatric implications of hepatitis-C infection

Critical Reviews in Neurobiology

Volumn 19, Issue 2-3, 2007, Pages 79-118

  Giunta, Brian ^a   Somboonwit, Charurut ^a   Nikolic, William V ^a   Rrapo, Elona ^a   Tan, Jun ^a   Shapshak, Paul ^a   Fernandez, Francisco ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Depression; Fatigue; Hepatitis C; Interferon alpha

Indexed keywords

ALPHA INTERFERON; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; DIAZEPAM; DULOXETINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; METHYLPHENIDATE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHENYTOIN; PLACEBO; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ACUTE CONFUSION; ADD ON THERAPY; ANOREXIA; ANXIETY DISORDER; ARTICLE; AUTONOMIC NEUROPATHY; BRAIN METASTASIS; COGNITIVE DEFECT; COMORBIDITY; DELIRIUM; DEPRESSION; DISORIENTATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPHORIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOMANIA; INSOMNIA; IRRITABILITY; LETHARGY; LIVER FAILURE; MAJOR DEPRESSION; MANIA; MELANOMA; MEMORY DISORDER; MENTAL DISEASE; NONHUMAN; PARKINSONISM; PLASMA HALF LIFE; POPULATION; PSYCHOMOTOR DISORDER; PSYCHOSIS; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; SUBSTANCE ABUSE; SWEATING; TREATMENT OUTCOME; VIRUS REPLICATION; WEIGHT REDUCTION;

EID: 68349101293     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v19.i2-3.20     Document Type: Article

References (160)

1. Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD. Hepatitis C treatment for people with severe mental illness. Psychosomatics. 2006;47:93-107.
2. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: Recognition and management. CNS Drugs. 2005;19:105-23.
3. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
4. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry. 2000;157:867-76.
5. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18;2316-26.
6. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942-7
7. Kraus, M.R, Schafer, A, Faller, H, Csef, H, Scheurlen, M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16: 1091-9.
8. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-6.
9. Bullock G, Bruns DM, Haverstick D. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem. 2002;48:2147-54.
10. Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, Nowicki M, Nikolopoulou GB, Vargas H, Rakela J. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol. 2002;76:10064-8.
11. Laskus, T, Radkowski, M, Wilkinson, J, Vargas, H, Rakela, J. The origin of hepatitis C virus reinfecting transplanted livers: serum-derived versus peripheral blood mononuclear cell-derived virus. J Infect Dis. 2002;185:417-21.
12. Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol. 1988;6:355-9.
13. Farkkila M, Iivanainen M, Roine R, Bergstrom L, Laaksonen R, Niemi ML, Cantell K. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand. 1984;70:42-6.
14. Mattson K, Niiranen A, Iivanainen M, Farkkila M, Bergstrom L, Holsti LR, Kauppinen HL, Cantell K. Neurotoxicity of interferon. Cancer Treat Rep. 1983;67;958-61.
15. Meyers CA, Obbens EA, Scheibel RS, Moser RP. Neurotoxicity of intra-ventricularly administered alpha-interferon for leptomeningeal disease. Cancer. 1991;68:88-92.
16. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147:1577-80.
17. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-51.
18. Loftis J, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord. 2004;82:175-190.
19. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest. 1995;13:561-6.
20. Licinio J, Kling MA, Hauser P. Cytokines and brain function: Relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol. 1998;25:30-8.
21. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, Corbera K, Raymond S, Lund S, Jacobson P. A double-blind trial of halo-peridol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153:231-7.
22. Hoffman RG, Cohen MA, Alfonso CA, Weiss JJ, Jones S, Keller M, Con-demarin JR, Chiu NM, Jacobson JM. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics. 2003;44:417-20.
23. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: A pilot study of exercise and methylphenidate. Oncol Nurs Forum. 2002;29:E85-90.
24. Lang JP, Michel L, Halleguen O. Treatment of affective disorder in hepatitis C. A prospective study in 50 patients. Ann Med Interne (Paris). 2002;153:2S22-30.
25. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha. Neuropsychobiology. 1998;37:93-7.
26. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999;354:131-2.
27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
28. Fried MW, Hadziyannis SJ. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis. 2004;24(Suppl 2):47-54.
29. Kraus MR, Schafer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics. 2000;41:377-84.
30. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003;64:708-14.
31. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-52.
32. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001b;344:961-6.
33. Capuron L, Ravaud A. Prediction of the depressive effects of inter-feron alfa therapy by the patient's initial affective state. N Engl J Med. 1999;340:1370.
34. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44:104-12.
35. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol. 2002;36:401-7.
36. Fontana RJ, Walsh J, Moyer CA, Lok AS, Webster S, Klein S. High-dose interferon alfa-2b and ribavirin in patients previously treated with in-terferon: results of a prospective, randomized, controlled trial. J Clin Gastroenterol. 2002;34:177-82.
37. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, Cheever LW, Cargill VA. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40(Suppl 5):S276 -85.
38. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, Garre JB. Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients. World J Biol Psychiatry. 2003;4:115-8.
39. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: Effect of interferon treatment. Dig Dis. 2002;20:284-8.
40. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72:237-41.
41. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: A prospective study. Gen Hosp Psychiatry. 2003;25:34-8.
42. Evans AA, London WT. Hepatitis B vaccine and liver problems in US children less than 6 years old. Epidemiology. 1999;10:790 -1.
43. Bluthe RM, Crestani F, Kelley KW, Dantzer R. Mechanisms of the behavioral effects of interleukin 1. Role of prostaglandins and CRF. Ann N Y Acad Sci. 1992;650:268-75.
44. Bluthe RM, Dantzer R, Kelley KW. Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res. 1992;573:318-20.
45. Bluthe RM, Sparber S, Dantzer R. Modulation of the behavioural effects of interleukin-1 in mice by nitric oxide. Neuroreport. 1992;3:207-9.
46. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry. 2003;160:1342-5.
47. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 1991;43:425-73.
48. Raines C, Radcliffe O, Treisman GJ. Neurologic and psychiatric complications of antiretroviral agents. J Assoc Nurses AIDS Care. 2005;16:35-48.
49. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol Today. 1999;20:469-73.
50. Moreno FA, McGavin C, Malan TP, Gelenberg AJ, Heninger GR, Mathe AA, Delgado PL. Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: Results from single lumbar puncture sampling technique. Int J Neuropsychopharmacol. 2000;3:277-83.
51. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375-88.
52. Schafer M, Schmidt F, Amann B, Schlosser S, Loeschke K, Grunze H. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology. 2000;42(Suppl 1):43-5.
53. Farah A. Interferon-induced depression treated with citalopram. J Clin Psychiatry. 2002;63:166-7.
54. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63:194-8.
55. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994;21:241-3.
56. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol. 1993;88:760-1.
57. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000;173:359-61.
58. Yoshida K, Higuchi H, Takahashi H, Shimizu T. Favorable effect of milnacipran on depression induced by interferon-alpha. J Neuropsychiatry Clin Neurosci. 2003;15:242-43.
59. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. an overview with emphasis on pharmacokinet-ics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32(Suppl 1):1-21.
60. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-20.
61. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000;28:1176-83.
62. Ahmed A, Keeffe EB. Update on chronic hepatitis C. Compr Ther. 2003;29:224-32.
63. Weinrieb RM, Auriacombe M, Lynch KG, Chang KM, Lewis JD. A critical review of selective serotonin reuptake inhibitor-associated bleeding: Balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry. 2003;64:1502-10.
64. Edwards IR. Withdrawing drugs: Nefazodone, the start of the latest saga. Lancet. 2003;361:1240.
65. Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: A case series. AIDS. 2003;17:638-640.
66. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-7.
67. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR, Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:1057-64.
68. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol. 2003;23:27-30.
69. Goodnick PJ, Sandoval R, Brickman A, Klimas NG. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry. 1992;32:834-8.
70. Goodnick PJ. Treatment of chronic fatigue syndrome with venlafaxine. Am J Psychiatry. 1996;153:294.
71. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7:468-73.
72. Raison CL, Miller AH. The neuroimmunology of stress and depression. Semin Clin Neuropsychiatry. 2001;6:277-94.
73. Carpiniello B, Orru MG, Baita A, Pariante CM, Farci G. Mania induced by withdrawal of treatment with interferon alfa. Arch Gen Psychiatry. 1998;55:88-9.
74. Kanno A, Yamada M, Abe M, Okamoto Y. A case of interferon alpha-induced manic psychosis in chronic hepatitis C. Tohoku J Exp Med. 1999;187:79-82.
75. Monji A, Yoshida I, Tashiro K, Hayashi Y, Tashiro N. A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C. Psychosomatics. 1998;39:562-4.
76. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry. 2004;161:429-35.
77. Gould RA, Ball S, Kaspi SP, Otto MW, Pollack MH, Shekhar A, Fava M. Prevalence and correlates of anger attacks: a two site study. J Affect Disord. 1996;39:31-8.
78. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152:1130-8.
79. Appels A. Why do imminent victims of a cardiac event feel so tired? Int J Clin Pract. 1997;51:447-50.
80. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry. 2003;160:172-4.
81. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476 -82.
82. Huckans MS, Blackwell AD, Harms TA, Hauser P. Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. Psychiatr Serv. 2006;57:403-6.
83. Osher FC, Goldberg RW, McNary SW, Swartz MS, Essock SM, Butterfield MI, Rosenberg SD, Five-Site Health and Risk Study Research Committee. Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatr Serv. 2003;54:842-7.
84. Patrick DM, Buxton JA, Bigham M, Mathias RG. Public health and hepatitis C. Can J Public Health. 2000;91(Suppl 1):S18-23.
85. Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among noninjecting drug users: A report. Subst Use Misuse. 2001;36:523-34.
86. An SF, Giometto B, Groves M, Miller RF, Beckett AA, Gray F, Tavolato B, Scaravilli F. Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS. J Neuropathol Exp Neurol. 1997;56:1262-8.
87. Stephenson J. Former addicts face barriers to treatment for HCV. JAMA. 2001;285:1003-5.
88. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction. 2004;99:1167-75.
89. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroen-terol. 2002;34:268-71.
90. Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, Fimmel CJ. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 2002;97:149-55.
91. Hatem C, Minello A, Bresson-Hadni S, Jooste V, Evrard P, Obert B, Lepage C, Bonithon-Kopp C, Faivre J, Monnet E, Miguet JP, Hillon P, REBOHC and REVHOC Committees. Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther. 2005; 21:1007-15.
92. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188-93.
93. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H, Construct Group. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 2002;8:45-9.
94. Robaeys G, Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg. 2005;68:55-67.
95. Loguercio C, Di Pierro M, Di Marino MP, Federico A, Disalvo D, Crafa E, Tuccillo C, Baldi F, del VecchioBlanco C. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: Prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol. 2000;35:296-301.
96. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, Ito S, Fujiwara K. Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996;91:1374-9.
97. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, Yamada Y, Abe H. Efficacy of interferon therapy in patients with chronic hepatitis C. comparison between non-drinkers and drinkers. Scand J Gas-troenterol. 1994;29:1039-43.
98. DHHS Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents; 2001 [cited 2009 April 21]. Available from: http://www. hivatis.org.
99. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381-90.
100. Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother. 1999;33:461-73.
101. Van Cleef GF, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy. 1997;17:774-8.
102. Preston SL, Postelnick M, Purdy BD, Petrolati J, Aasi H, Stein DS. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. AIDS. 1998,12:228-30.
103. Rabkin JG, Ferrando S. A 'second life' agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome. Arch Gen Psychiatry. 1997;54:1049-53.
104. Jennings HR, Romanelli F. The use of valproic acid in HIV-positive patients. Ann Pharmacother. 1999;33:1113-6.
105. Jennings HR, Romanelli F. Comment: risk of drug-disease and disease-drug interactions with anticonvulsants in HIV-positive patients [letter; comment]. Ann Pharmacother. 1999;33:1373-4.
106. Romanelli F, Jennings HR, Nath A, Ryan M, Berger J. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology. 2000;54:1404-7
107. Maggi JD, Halman MH. The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Can J Psychiatry. 2001;46:322-7.
108. Bolay H, Söylemezoǧlu F, Nurlu G, Tuncer S, Varli K. PCR detected hepatitis C virus genome in the brain of a case with progressive encephalomyelitis with rigidity. Clin Neurol Neurosurg. 1996;98:305-8.
109. Caudai C, Maimone D, Almi P, Annunziata P, Bastianoni I, Boggiano CA, Guazzi GC, Padula M, Valensin PE. The potential role of hepatitis C virus in the pathogenesis of the neurological syndrome in chronic hepatitis C. Gut. 1997;41:411-2.
110. Origgi L, Vanoli M, Carbone A, Grasso M, Scorza R. Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci. 1998;315:208-10.
111. Morsica G, Bernardi MT, Novati R, Uberti Foppa C, Castagna A, Lazzarin A. Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. J Med Virol. 1997;53:252-4.
112. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, Rakela J, Laskus T. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. 2002;76:600-8.
113. Epstein LG, Kuiken C, Blumberg BM, Hartman S, Sharer LR, Clement M, Goudsmit J. HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology. 1991;180:583-90.
114. Goulding C, O'Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol. 2001;13:507-11.
115. Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci. 1997;42:186-191.
116. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000;49:311-7.
117. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209-12.
118. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, Taylor-Robinson SD. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS. 2005;Suppl 3:S53-63.
119. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol. 1998;93:785-9.
120. McDonald J, Jayasuriya J, Bindley P, Gonsalvez C, Gluseska S. Fatigue and psychological disorders in chronic hepatitis C. J Gastroenterol Hepatol. 2002;17:171-6.
121. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculo-skeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999;94:1355-60.
122. Cacoub P, Ratziu V, Myers RP, Ghillani P, Piette JC, Moussalli J, Poynard T, Multivirc Group. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol. 2002;36:812-8.
123. Goh J, Coughlan B, Quinn J, O'Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 1999;11:833-8.
124. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. irish hepatology research group. N Engl J Med. 1999;340:1228-33.
125. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-6.
126. Glacken M, Coates V, Kernohan G, Hegarty J. The experience of fatigue for people living with hepatitis C. J Clin Nurs. 2003;12:244-52.
127. Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroen-terol. 2001;32:413-7.
128. Wessely S, Pariante C. Fatigue, depression and chronic hepatitis C infection. Psychol Med. 2002;32:1-10.
129. Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology. 1997;26:15S-20S.
130. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-21.
131. Sherlock S, Summerskill WH, White LP, Phear EA. Portal-systemic encephalopathy; neurological complications of liver disease. Lancet. 1954;267:454-7.
132. Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol. 1999;31(Suppl 1):152-9.
133. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433 -9.
134. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35:440-6.
135. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003;9:847-54.
136. Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Vargas V, Esteban R, Guardia J. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol. 2003;39:231-8.
137. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, Taylor-Robinson SD. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS. 2005;19(Suppl 3):S53-63.
138. Rogers RD, Robbins TW. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr Opin Neurobiol. 2001;11:250-7.
139. Grant I, Adams KM, Carlin AS, Rennick PM, Judd LL, Schooff K, Reed R. Organic impairment in polydrug users: Risk factors. Am J Psychiatry. 1978;135:178-84.
140. Davis PE, Liddiard H, McMillan TM. Neuropsychological deficits and opiate abuse. Drug Alcohol Depend. 2002;67:105-8.
141. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schüler A, Ennen JC, Ahl B, Manns MP, Böker KW. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41:845-51.
142. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, Mouradian MM, Sadler AE, Keilp J. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: Relationship to clinical and neurological status. Ann Neurol. 1991;29:202-9.
143. Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, Grant I. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005;64:1343-7.
144. Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, Cherner M, Heaton R, Ellis R, Everall IP, Grant I, Masliah E, HIV Neurobehavioral Research Center Group. Pathogenesis of hepatitis C virus coinfection. J Infect Dis. 2007;196:361-70.
145. Fossati G, Taramelli D, Balsari A, Bogdanovich A, Andreola G, Parmiani G. Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int J Cancer. 1984;33:591-7.
146. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol. 1986;22:610-2.
147. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in malignant melanoma. Cancer Treat. 1984;68:1403-5.
148. Jonkman JHG, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Ooster-huis B, De Noord OE, Guentert TW. Effects of a-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharm. 1989;27:795-802.
149. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet. 1987;2:939-41.
150. Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology. 1993;17:65-9.
151. Foung SKH, Perkins S, Raubitschek A, Larrick J, Lizak G, Fishwald D, Engelman EG, Grumet FC. Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. J Immunol Methods. 1984;70:83-90.
152. Rendic S, Di Carlo FI. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29:413-580.
153. Gaeta G, Precone D, Felaco F, Bruno R, Spadaro A, Stornaiuolo G, Stanzione M, Ascione T, De Sena R, Campanone A, Filice G, Piccinino F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multi-centre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1633-9.
154. Russo M, Fried M. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003; 124:1711-9.
155. Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL Jr. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat. 2000;7:211-7.
156. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology. 2000;31:1207-11.
157. Raison C, Broadwell S, Borisov A, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun. 2005;19:23-7.
158. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66:41-8.
159. Raison C, Woolwine B, Demetrashvili M, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25:1163-74.
160. Morasco B, Rifai M, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103:83-90.